COMPANY RESEARCHDBV Technologies SA
DBV Technologies is a France-based biopharmaceutical company developing epicutaneous immunotherapies for allergic conditions. Its technology is designed to deliver allergens through the skin to help modulate immune responses, with development efforts focused on food allergies and related diseases. DBV has research and clinical development activities aimed at evaluating this approach in patients with significant unmet needs. The company's ordinary shares trade on Euronext Paris under DBV, while American depositary shares trade on Nasdaq under DBVT. These are different securities linked to one issuer, not separate company records.
Company at a glance
Corporate information
- Company entity
- DBV Technologies SA
- Headquarters / principal office
- France
- Founded
- Not verified
- Ownership / capital status
- Publicly tradedPublicly listed
- Official corporate reference
- https://dbv-technologies.com/
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-08 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
Euronext Paris: DBV Nasdaq: DBVT
epicutaneous immunotherapy · allergen delivery
food allergy · immunology
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
DBV Technologies is a France-based biopharmaceutical company developing epicutaneous immunotherapies for allergic conditions. Its technology is designed to deliver allergens through the skin to help modulate immune responses, with development efforts focused on food allergies and related diseases. DBV has research and clinical development activities aimed at evaluating this approach in patients with significant unmet needs. The company's ordinary shares trade on Euronext Paris under DBV, while American depositary shares trade on Nasdaq under DBVT. These are different securities linked to one issuer, not separate company records.
Business, technology & evidence
- SecuritiesEuronext Paris: DBV / Nasdaq: DBVT
Individual program detail is not recorded. Consult the original sources below.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- Official issuer and R&D disclosure · DBV Technologies SA ↗DBV Technologies SA ·
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.